CD4 and cancer: The fraction of PD1 expressing CD4+ T lymphocytes, CD4+Foxp3− Teff cells and CD4+Foxp3+ Tregs was not significantly different from healthy controls in cancer patients before or at various time points after brachytherapy (Figure 4A–C).